Gujarat Alkalies & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2025, 2:38 pm

Competitors of Gujarat Alkalies & Chemicals Ltd

All Competitor Stocks of Gujarat Alkalies & Chemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 10:00 am

Below is a detailed analysis of the quarterly data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,105.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,075.00 Cr. (Mar 2025) to 1,105.00 Cr., marking an increase of 30.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,010.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 974.00 Cr. (Mar 2025) to 1,010.00 Cr., marking an increase of 36.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 6.00 Cr..
• For OPM %, as of Jun 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00%.
• For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 16.00 Cr..
• For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 5.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -12.00 Cr., marking a decrease of 22.00 Cr..
• For Tax %, as of Jun 2025, the value is 15.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 15.00%, marking an increase of 2.00%.
• For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 23.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -1.88. The value appears to be declining and may need further review. It has decreased from 1.20 (Mar 2025) to -1.88, marking a decrease of 3.08.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:17 am

Growth

Last Updated: September 5, 2025, 5:30 am

Balance Sheet

Last Updated: November 9, 2025, 2:07 pm

Below is a detailed analysis of the balance sheet data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 73.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 73.00 Cr..
• For Reserves, as of Sep 2025, the value is 5,497.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,596.00 Cr. (Mar 2025) to 5,497.00 Cr., marking a decrease of 99.00 Cr..
• For Borrowings, as of Sep 2025, the value is 637.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 561.00 Cr. (Mar 2025) to 637.00 Cr., marking an increase of 76.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 2,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,756.00 Cr. (Mar 2025) to 2,002.00 Cr., marking an increase of 246.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 8,209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 4,522.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,584.00 Cr. (Mar 2025) to 4,522.00 Cr., marking a decrease of 62.00 Cr..
• For CWIP, as of Sep 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 79.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 42.00 Cr..
• For Investments, as of Sep 2025, the value is 2,044.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,976.00 Cr. (Mar 2025) to 2,044.00 Cr., marking an increase of 68.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,607.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,348.00 Cr. (Mar 2025) to 1,607.00 Cr., marking an increase of 259.00 Cr..
• For Total Assets, as of Sep 2025, the value is 8,209.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..

Notably, the Reserves (5,497.00 Cr.) exceed the Borrowings (637.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gujarat Alkalies & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
• For Diluted EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
• For Cash EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 33.38 (Mar 24) to 55.57, marking an increase of 22.19.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 554.60. It has increased from 518.34 (Mar 24) to 554.60, marking an increase of 36.26.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 61.62. This value is within the healthy range. It has increased from 30.79 (Mar 24) to 61.62, marking an increase of 30.83.
• For PBIT / Share (Rs.), as of Mar 25, the value is 8.21. This value is within the healthy range. It has increased from -20.60 (Mar 24) to 8.21, marking an increase of 28.81.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from -26.67 (Mar 24) to 1.32, marking an increase of 27.99.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from -18.01 (Mar 24) to 2.15, marking an increase of 20.16.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 2. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
• For PBDIT Margin (%), as of Mar 25, the value is 11.11. This value is within the healthy range. It has increased from 5.93 (Mar 24) to 11.11, marking an increase of 5.18.
• For PBIT Margin (%), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 10. It has increased from -3.97 (Mar 24) to 1.47, marking an increase of 5.44.
• For PBT Margin (%), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 10. It has increased from -5.14 (Mar 24) to 0.23, marking an increase of 5.37.
• For Net Profit Margin (%), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 5. It has increased from -3.47 (Mar 24) to 0.38, marking an increase of 3.85.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.59. This value is below the healthy minimum of 8. It has increased from -6.22 (Mar 24) to -1.59, marking an increase of 4.63.
• For Return on Networth / Equity (%), as of Mar 25, the value is -1.14. This value is below the healthy minimum of 15. It has increased from -3.89 (Mar 24) to -1.14, marking an increase of 2.75.
• For Return on Capital Employeed (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 0.85, marking an increase of 2.92.
• For Return On Assets (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 5. It has increased from -2.95 (Mar 24) to -0.81, marking an increase of 2.14.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.50. It has increased from 0.46 (Mar 24) to 0.50, marking an increase of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.13, marking a decrease of 0.10.
• For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.67 (Mar 24) to 0.60, marking a decrease of 0.07.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.12. This value exceeds the healthy maximum of 8. It has increased from 6.75 (Mar 24) to 9.12, marking an increase of 2.37.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -156.19. This value is below the healthy minimum of 20. It has decreased from -73.02 (Mar 24) to -156.19, marking a decrease of 83.17.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.08. This value is within the healthy range. It has decreased from 123.03 (Mar 24) to 31.08, marking a decrease of 91.95.
• For Earning Retention Ratio (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.92. This value is within the healthy range. It has increased from -23.03 (Mar 24) to 68.92, marking an increase of 91.95.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.95. This value is within the healthy range. It has increased from 5.07 (Mar 24) to 8.95, marking an increase of 3.88.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has increased from -1.97 (Mar 24) to 1.31, marking an increase of 3.28.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,670.05. It has decreased from 5,324.43 (Mar 24) to 4,670.05, marking a decrease of 654.38.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.15, marking a decrease of 0.25.
• For EV / EBITDA (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 23.55 (Mar 24) to 10.32, marking a decrease of 13.23.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
• For Retention Ratios (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
• For Price / BV (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.81 (Mar 24) to 0.75, marking a decrease of 0.06.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
• For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness